An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis

References

• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43:461–466.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006;5:1597–1601.
   PubMed Web of Science ®Google Scholar
• Ame-Thomas P, Maby-El HH, Monvoisin C, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007;109:693–702.
   PubMed Web of Science ®Google Scholar
• Guilloton F, Caron G, Menard C, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood. 2012;119:2556–2567.
   PubMed Web of Science ®Google Scholar
• Goval JJ, Thielen C, Bourguignon C, et al. The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP. Haematologica. 2008;93:1169–1177.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Lee Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues; 2008.
   Google Scholar
• Ott G, Katzenberger T, Greiner A, et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res. 1997;57:3944–3948.
   PubMed Web of Science ®Google Scholar
• Sonnenberg M, van der KH, Haubeis S, et al. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer. 2008;8:364.
   PubMed Web of Science ®Google Scholar
• Horn H, Bausinger J, Staiger AM, et al. Numerical and structural genomic aberrations are reliably detectable in tissue microarrays of formalin-fixed paraffin-embedded tumor samples by fluorescence in-situ hybridization. PLoS One. 2014;9:e95047.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.
   PubMed Web of Science ®Google Scholar
• Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.
   PubMed Web of Science ®Google Scholar
• Kurose K, Gilley K, Matsumoto S, et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet. 2002;32:355–357.
   PubMed Web of Science ®Google Scholar
• Lafkas D, Trimis G, Papavassiliou AG, et al. P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int J Cancer. 2008;123:967–971.
   PubMed Web of Science ®Google Scholar
• Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008;40:650–655.
   PubMed Web of Science ®Google Scholar
• Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155:53–64.
   PubMed Web of Science ®Google Scholar
• Singh RR, Kunkalla K, Qu C, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011;30:4874–4886.
   PubMed Web of Science ®Google Scholar
• Yagi K, Yamamoto K, Umeda S, et al. Expression of multidrug resistance 1 gene in B-cell lymphomas: association with follicular dendritic cells. Histopathology. 2013;62:414–420.
   PubMed Web of Science ®Google Scholar
• Haubeiss S, Schmid JO, Murdter TE, et al. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010;9:168.
   PubMed Web of Science ®Google Scholar
• Schmid JO, Dong M, Haubeiss S, et al. Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin. Cancer Res. 2012;72:5824–5832.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604–4613.
   PubMed Web of Science ®Google Scholar
• Bardin N, George F, Mutin M, et al. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens. 1996;48:531–539.
   PubMedGoogle Scholar
• Bardin N, Frances V, Lesaule G, et al. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun. 1996;218:210–216.
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008;68:4331–4339.
   PubMed Web of Science ®Google Scholar
• Philippe J, Louagie H, Thierens H, et al. Quantification of apoptosis in lymphocyte subsets and effect of apoptosis on apparent expression of membrane antigens. Cytometry. 1997;29:242–249.
   PubMedGoogle Scholar
• Craig M, Hanna WT, Cabanillas F, et al. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2014;166:920–928.
   PubMed Web of Science ®Google Scholar
• Yun H, Zhang HL, Wang HQ. Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. Med Oncol. 2015;32:353.
   PubMed Web of Science ®Google Scholar
• Sadlonova A, Bowe DB, Novak Z, et al. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2009;2:9–21.
   PubMedGoogle Scholar
• Grillot DA, Merino R, Pena JC, et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med. 1996;183:381–391.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Ahmed AA, Moller C, et al. Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. J Exp Med. 2001;194:1561–1569.
   PubMed Web of Science ®Google Scholar
• Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene. 2007;26:5828–5832.
   PubMed Web of Science ®Google Scholar
• Scarfo L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;155:36–39.
   PubMed Web of Science ®Google Scholar
• Andreadis C, Gimotty PA, Wahl P, et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007;109:3409–3416.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–234.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Rolver L, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007;25:3330–3336.
   PubMed Web of Science ®Google Scholar